SK Bioscience Co

SK Bioscience Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of SK Bioscience Co (302440.KS) as of Nov 4, 2026 is -31.28. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -27.90 — a change of 12.09% (lower).

EV/EBIT

-31.28

YoY

12.09%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of SK Bioscience Co is 2025 -31.28 . EV/EBIT (Enterprise Value to EBIT) of SK Bioscience Co was 2024 -27.90 . It decreases by 12.09% lower compared to the previous year.

The SK Bioscience Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
597.18 KRW
Jan 1, 2020
102.44 KRW
Jan 1, 2021
8.15 KRW
Jan 1, 2022
33.59 KRW
Jan 1, 2023
-322.24 KRW
Jan 1, 2024
-27.90 KRW
Jan 1, 2025
-31.28 KRW
Jan 1, 2026 (e)
-40.45 KRW
The SK Bioscience Co EV/EBIT history
YEAREV/EBITYoY
est-40.45+29.32%
-31.28+12.09%
-27.90-91.34%
-322.24-1,059.43%
33.59+312.32%
8.15-92.05%
102.44-82.85%
597.18-49.23%
1,176.37—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SK Bioscience Co Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides SK Bioscience Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates SK Bioscience Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots SK Bioscience Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if SK Bioscience Co grows earnings faster than its peers.

SK Bioscience Co Stock analysis

What does SK Bioscience Co do? SK Bioscience Co Ltd is a South Korean biotechnology company headquartered in Seongnam, Gyeonggi-Do. The company went public on March 18, 2021, with its stock listed on the Korean Stock Exchange under the ticker 302440.KS. It operates within the health care sector, specifically in the biotechnology industry. SK Bioscience employs 1,067 people and focuses on the development and distribution of bio and vaccine products. The company distributes its products both domestically and internationally. While specific product names are mentioned in unverified sources, the company is known to be involved in the production of vaccines and infusion solutions. It also engages in technology export business, though detailed information about its technology or export markets is not provided. The company's website is https://www.skbioscience.co.kr/, where further information about its operations and products may be available. SK Bioscience does not disclose specific details about its product lines beyond the general categories of vaccines and infusion solutions, and it does not provide information on acquisitions, founding year, or key personnel. The company's activities are centered around biotechnology and healthcare, with a focus on vaccine development and distribution. Its market presence spans both domestic and international markets, though specific regions or countries are not specified. The company's financial data, including revenue and market capitalization, is not included in the provided information. SK Bioscience is a publicly traded company with a focus on biotechnology and healthcare innovation. SK Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SK Bioscience Co stock

EV/EBIT (Enterprise Value to EBIT) of SK Bioscience Co is -31.28 in 2025.

EV/EBIT (Enterprise Value to EBIT) of SK Bioscience Co changed from -27.90 to -31.28, representing a 12.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) SK Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s SK Bioscience Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — SK Bioscience Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — SK Bioscience Co